IPI Legacy Liquidation Co financial data

Industry
Pharmaceutical Preparations
Location
201 Elliott Ave. W, Suite 260, Seattle, WA
State of incorporation
DE
Fiscal year end
April 26
Former names
IMPEL PHARMACEUTICALS INC (to 2/15/2024), IMPEL NEUROPHARMA INC (to 4/14/2022)
Latest financial report
10-Q - Q3 2023 - Nov 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 64.7 % -88.8%
Quick Ratio 10.4 % -65.8%
Debt-to-equity -181 % -127%
Return On Equity 103 %
Return On Assets -127 % -39%
Operating Margin -341 % +68.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.9M shares +0.68%
Common Stock, Shares, Outstanding 23.7M shares +0.04%
Entity Public Float 120M USD +206%
Common Stock, Value, Issued 24K USD 0%
Weighted Average Number of Shares Outstanding, Basic 23.7M shares +0.17%
Weighted Average Number of Shares Outstanding, Diluted 23.7M shares +0.17%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 21M USD +155%
Cost of Revenue 9.95M USD +111%
Research and Development Expense 4.16M USD -72.2%
General and Administrative Expense 77M USD -0.95%
Operating Income (Loss) -71.6M USD +19.7%
Nonoperating Income (Expense) -1M USD +89.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -74.3M USD +31.2%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -74.3M USD +31.2%
Earnings Per Share, Basic -3.12 USD/shares +55.7%
Earnings Per Share, Diluted -3.12 USD/shares +55.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 239K USD -99.7%
Accounts Receivable, after Allowance for Credit Loss, Current 6.59M USD +7.46%
Inventory, Net 6.86M USD -20.4%
Other Assets, Current 621K USD -19.6%
Assets, Current 23.4M USD -76.4%
Property, Plant and Equipment, Net 4.09M USD +47.2%
Operating Lease, Right-of-Use Asset 3.73M USD +27.2%
Other Assets, Noncurrent 3.83M USD +1948%
Assets 35.1M USD -66.7%
Accounts Payable, Current 3.73M USD -21.4%
Accrued Liabilities, Current 8.45M USD -28.1%
Liabilities, Current 125M USD +525%
Operating Lease, Liability, Noncurrent 2.24M USD +41.1%
Liabilities 127M USD -0.38%
Retained Earnings (Accumulated Deficit) -372M USD -24.9%
Stockholders' Equity Attributable to Parent -91.9M USD -312%
Liabilities and Equity 35.1M USD -66.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.1M USD +0.28%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -1.05M USD -12975%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 23.7M shares +0.04%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -25.2M USD -161%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.74M USD -94.1%
Deferred Tax Assets, Valuation Allowance 78.8M USD +49.3%
Deferred Tax Assets, Gross 80M USD +51.5%
Operating Lease, Liability 3.8M USD +29.6%
Payments to Acquire Property, Plant, and Equipment 1.05M USD +12975%
Property, Plant and Equipment, Gross 8.97M USD +27.1%
Operating Lease, Liability, Current 1.56M USD +16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 718K USD -33.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.57M USD +9.02%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +56.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.1M USD +557%
Lessee, Operating Lease, Liability, to be Paid, Year Three 292K USD +47.5%
Deferred Tax Assets, Operating Loss Carryforwards 68M USD +52.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.77M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.83M USD
Additional Paid in Capital 280M USD +1.69%
Deferred Tax Assets, Net of Valuation Allowance 1.16M USD
Share-based Payment Arrangement, Expense 4.74M USD +26.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%